← All trials
NCT04414969
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2020
- Primary completion
- Jul 1, 2022
- Completion date
- Jul 1, 2025
- First posted
- Jun 3, 2020
- Last posted
- Jun 3, 2020
- Enrollment
- 35
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Central South UniversityLead sponsor
- Central South UniversityReponsible party - principal investigator
- Department of Lymphoma and Hematology, Hunan Cancer HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.